GFAP and Alzheimer disease: Whilst plasma Aβ1–42/1–40 may also function well as a plasma biomarker of Aβ pathology, plasma GFAP appears to give a much broader picture of the state of the individual, hence it may better function as a surrogate plasma biomarker for Aβ pathology in AD.